The roles of factor Va and protein S in formation of the activated protein C/protein S/factor Va inactivation complex.


Journal

Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508

Informations de publication

Date de publication:
12 2019
Historique:
received: 06 03 2019
accepted: 26 07 2019
pubmed: 1 8 2019
medline: 9 9 2020
entrez: 1 8 2019
Statut: ppublish

Résumé

Activated protein C (APC)-mediated inactivation of factor (F)Va is greatly enhanced by protein S. For inactivation to occur, a trimolecular complex among FVa, APC, and protein S must form on the phospholipid membrane. However, direct demonstration of complex formation has proven elusive. To elucidate the nature of the phospholipid-dependent interactions among APC, protein S, and FVa. We evaluated binding of active site blocked APC to phospholipid-coated magnetic beads in the presence and absence of protein S and/or FVa. The importance of protein S and FV residues were evaluated functionally. Activated protein C alone bound weakly to phospholipids. Protein S mildly enhanced APC binding to phospholipid surfaces, whereas FVa did not. However, FVa together with protein S enhanced APC binding (>14-fold), demonstrating formation of an APC/protein S/FVa complex. C4b binding protein-bound protein S failed to enhance APC binding, agreeing with its reduced APC cofactor function. Protein S variants (E36A and D95A) with reduced APC cofactor function exhibited essentially normal augmentation of APC binding to phospholipids, but diminished APC/protein S/FVa complex formation, suggesting involvement in interactions dependent upon FVa. Similarly, FVa FVa plays a central role in the formation of its inactivation complex. Furthermore, membrane proximal interactions among FVa, APC, and protein S are essential for its cofactor function.

Sections du résumé

BACKGROUND
Activated protein C (APC)-mediated inactivation of factor (F)Va is greatly enhanced by protein S. For inactivation to occur, a trimolecular complex among FVa, APC, and protein S must form on the phospholipid membrane. However, direct demonstration of complex formation has proven elusive.
OBJECTIVES
To elucidate the nature of the phospholipid-dependent interactions among APC, protein S, and FVa.
METHODS
We evaluated binding of active site blocked APC to phospholipid-coated magnetic beads in the presence and absence of protein S and/or FVa. The importance of protein S and FV residues were evaluated functionally.
RESULTS
Activated protein C alone bound weakly to phospholipids. Protein S mildly enhanced APC binding to phospholipid surfaces, whereas FVa did not. However, FVa together with protein S enhanced APC binding (>14-fold), demonstrating formation of an APC/protein S/FVa complex. C4b binding protein-bound protein S failed to enhance APC binding, agreeing with its reduced APC cofactor function. Protein S variants (E36A and D95A) with reduced APC cofactor function exhibited essentially normal augmentation of APC binding to phospholipids, but diminished APC/protein S/FVa complex formation, suggesting involvement in interactions dependent upon FVa. Similarly, FVa
CONCLUSIONS
FVa plays a central role in the formation of its inactivation complex. Furthermore, membrane proximal interactions among FVa, APC, and protein S are essential for its cofactor function.

Identifiants

pubmed: 31364267
doi: 10.1111/jth.14594
pmc: PMC6916587
pii: S1538-7836(22)03081-1
doi:

Substances chimiques

Calcium-Binding Proteins 0
Multiprotein Complexes 0
PROS1 protein, human 0
Phospholipids 0
Protein C 0
Protein S 0
Factor Va 65522-14-7
Thromboplastin 9035-58-9
Thrombin EC 3.4.21.5

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2056-2068

Subventions

Organisme : British Heart Foundation
ID : PG/14/90/31219
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/14/63/31036
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/10/004/28165
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/17/42/33039
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/12/60/29874
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/18/3/33405
Pays : United Kingdom

Informations de copyright

© 2019 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.

Références

Blood. 1982 Jul;60(1):59-63
pubmed: 7082847
Blood. 2011 Jun 16;117(24):6685-93
pubmed: 21508412
J Biol Chem. 1998 Nov 20;273(47):31086-91
pubmed: 9813008
J Biol Chem. 1999 Dec 17;274(51):36187-92
pubmed: 10593904
Blood. 2010 Jun 10;115(23):4878-85
pubmed: 20308596
J Biol Chem. 1986 Jul 25;261(21):9684-93
pubmed: 3755431
J Biol Chem. 1981 Nov 10;256(21):11128-31
pubmed: 6457049
J Thromb Haemost. 2008 Jan;6(1):83-9
pubmed: 17973648
Arterioscler Thromb Vasc Biol. 2002 Apr 1;22(4):530-8
pubmed: 11950687
J Biol Chem. 2003 Apr 25;278(17):14614-21
pubmed: 12560338
J Biol Chem. 2002 Dec 20;277(51):50022-9
pubmed: 12384508
J Biol Chem. 1984 Oct 10;259(19):11631-4
pubmed: 6480575
Thromb Haemost. 2012 Jan;107(1):15-21
pubmed: 22116556
J Biol Chem. 2017 Jun 2;292(22):9335-9344
pubmed: 28420729
Blood. 2002 Jul 15;100(2):524-30
pubmed: 12091344
Blood. 2001 Mar 15;97(6):1549-54
pubmed: 11238089
J Biol Chem. 1980 Jan 10;255(1):274-83
pubmed: 7350159
Blood. 1998 Feb 15;91(4):1140-4
pubmed: 9454742
Semin Thromb Hemost. 2009 Jun;35(4):382-9
pubmed: 19598066
Blood. 2014 Jun 19;123(25):3979-87
pubmed: 24740810
J Biol Chem. 1990 Jun 5;265(16):9072-6
pubmed: 2140568
J Thromb Haemost. 2009 Dec;7(12):1951-61
pubmed: 19765210
Nature. 1994 May 5;369(6475):64-7
pubmed: 8164741
Semin Thromb Hemost. 2013 Sep;39(6):613-20
pubmed: 23852824
Thromb Res. 2014 Jul;134(1):144-52
pubmed: 24835672
J Biol Chem. 2006 Sep 29;281(39):28850-7
pubmed: 16867987
J Biol Chem. 1995 Sep 8;270(36):21158-66
pubmed: 7673148
Biochem J. 1983 Mar 1;209(3):857-63
pubmed: 6223626
J Biol Chem. 2004 May 14;279(20):21643-50
pubmed: 15004010
Blood. 2003 Mar 15;101(6):2277-84
pubmed: 12446455
Thromb Haemost. 2013 Aug;110(2):275-82
pubmed: 23892573
Nature. 1999 Nov 25;402(6760):434-9
pubmed: 10586886
Blood. 2008 Mar 15;111(6):3034-41
pubmed: 18160668
J Biol Chem. 1993 Aug 5;268(22):16788-94
pubmed: 7688369
J Thromb Haemost. 2017 Jul;15(7):1241-1250
pubmed: 28671348
J Biol Chem. 1986 Sep 15;261(26):12022-7
pubmed: 2943733
J Biol Chem. 2003 Jul 4;278(27):24904-11
pubmed: 12707283
J Thromb Haemost. 2019 Dec;17(12):2056-2068
pubmed: 31364267
J Biol Chem. 1998 Apr 10;273(15):9031-40
pubmed: 9535891
EMBO J. 1996 Dec 16;15(24):6822-31
pubmed: 9003757
J Biol Chem. 1998 Jun 26;273(26):16140-5
pubmed: 9632668
Thromb Haemost. 2004 Jan;91(1):16-27
pubmed: 14691564
J Biol Chem. 1999 Feb 26;274(9):5462-8
pubmed: 10026158
Biochem J. 1983 Mar 1;209(3):847-56
pubmed: 6223625
Biochemistry. 1997 Apr 29;36(17):5120-7
pubmed: 9136872
Thromb Haemost. 2013 Feb;109(2):187-98
pubmed: 23224054
Blood. 1998 Feb 15;91(4):1135-9
pubmed: 9454741
FEBS Lett. 1998 Aug 14;433(1-2):28-32
pubmed: 9738926
J Comput Aided Mol Des. 1997 May;11(3):293-304
pubmed: 9263856
Blood. 2014 Apr 10;123(15):2420-8
pubmed: 24523236
J Biol Chem. 1994 Aug 19;269(33):21051-8
pubmed: 8063724
J Biol Chem. 2008 Aug 15;283(33):22573-81
pubmed: 18519572

Auteurs

Magdalena Gierula (M)

Centre for Haematology, Imperial College London, London, UK.

Isabelle I Salles-Crawley (II)

Centre for Haematology, Imperial College London, London, UK.

Salvatore Santamaria (S)

Centre for Haematology, Imperial College London, London, UK.

Adrienn Teraz-Orosz (A)

Centre for Haematology, Imperial College London, London, UK.

James T B Crawley (JTB)

Centre for Haematology, Imperial College London, London, UK.

David A Lane (DA)

Centre for Haematology, Imperial College London, London, UK.

Josefin Ahnström (J)

Centre for Haematology, Imperial College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH